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Abstract
Introduction: In the 1980s, the idea evolved that some individuals with normal weight (Metabolically Obese, Normal-Weight), who probably 
have increased abdominal fat, have metabolic disturbances related to obesity. This observation initiated the concept of the metabolically 
obese but normal-weight syndrome (MONW). Since then, there have been only a few studies in non-obese subjects. MONW men and 
women should be regarded as at high risk for cardiovascular disease.
Material and method: A group of 854 randomly chosen non-obese men and women, 20–40 years of age, was selected from three different 
areas of Poland — Szczecin, Krakow and Wroclaw. All subjects were interviewed and underwent physical examination, anthropometric 
measurements (waist circumference, hip circumference, BMI and WHR) as well as densitometry (total body DPX, total fat, android/gynoid 
deposit). Serum level of fasting glucose and insulin, indices of insulin sensibility (QUICKI) and insulin resistance (HOMA, FIRI), total cho-
lesterol, triglycerides and HDL-C were measured using commercially available kits. LDL-C level was calculated using Friedewald’s formula.
Results: The total amassed fatty tissue and its android deposit was found to be significantly greater in MONW men and women. MONW 
women were found to exhibit increased levels of triglycerides and LDL-C but lower levels of HDL-C. In women with excess abdominal 
fat (EAF), fasting glucose and insulin levels, HOMA and FIRI were considerably higher, while QUICKI was lower. Triglyceride and LDL-C 
levels were also higher while HDL-C levels were lower. In men with EAF, increased levels of total cholesterol and LDL-C were confirmed.
Conclusions: The occurrence of MONW is contingent upon the diagnosis criterion and increases when the criterion represents the value 
of HOMA — 21.76% in women and 31.42% in men. The frequency of MONW occurrence is lower when the criterion for abdominal fat 
content limit is used, amounting to 15.78% in women and 7.83% in men. (Endokrynol Pol 2012; 63 (6): 447–455)
Key words: insulin resistance, metabolic syndrome, fat distribution 
Streszczenie
Wstęp: W latach 80. zaobserwowano, że u nieotyłych osób, które gromadzą nadmierną ilość tkanki tłuszczowej w okolicy brzucha, rozwijają 
się powikłania metaboliczne charakterystyczne dla otyłości. Powstała wówczas koncepcja zespołu metabolicznej otyłości z prawidłową 
masą ciała — MONW (Metabolically Obese Normal-Weight). W Polsce badania takie nie były dotychczas prowadzone. Identyfikacja ludzi 
obciążonych tym zespołem pozwoliłaby na wczesne podjęcie działań prewencyjnych.
Materiał i metody: Zbadano 854 nieotyłych kobiet i mężczyzn, wybranych losowo w 3 regionach kraju – Szczecina, Krakowa, Wrocławia 
w wieku 20–40 lat. Przeprowadzono wywiad lekarski, badanie fizykalne, pomiary antropometryczne (obwód talii, bioder, BMI, WHR), 
badanie denzytometryczne (total body DPX; total fat; android/gynoid deposit). Ilość i dystrybucję tkanki tłuszczowej oceniano przy użyciu 
podwójnej absorpcjometrii energii RTG-DXA. W surowicy krwi oznaczono stężenie glukozy i insuliny na czczo, stężenie cholesterolu 
całkowitego, triglicerydów oraz HDL-C i wyliczono stężenie LDL-C oraz wartości wskaźników insulinowrażliwości (QUICKI) i insulino-
oporności (HOMA, FIRI). 
Wyniki: U kobiet i mężczyzn całkowita ilość tkanki tłuszczowej i jej androidalnego depozytu były istotnie wyższe w grupie z MONW. 
Stężenia glukozy i insuliny na czczo oraz wartości HOMA i FIRI były istotnie wyższe, a QIUCKI istotnie niższe u badanych z MONW. 
U kobiet z MONW stwierdzano istotnie wyższe stężenia trójglicerydów oraz LDL-C natomiast znacząco niższe stężenia HDL-C. Istotnych 
różnic nie było u mężczyzn. 
Wnioski: Częstość występowania metabolicznej otyłości z prawidłową masą ciała zależy od kryterium rozpoznania i jest większa, gdy 
kryterium to stanowi wielkość HOMA — 21,76% kobiet i 31,42% mężczyzn i mniejsza, gdy posługiwano się kryterium granicznej ilości 
tłuszczu brzusznego — częstość rozpoznania MONW wynosi — 15,78% u kobiet i 7,83% u mężczyzn. (Endokrynol Pol 2012; 63 (6): 447–455)
Słowa kluczowe: insulinooporność, zespół metaboliczny, dystrybucja tkanki tłuszczowej
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Introduction
Obesity is associated with a higher risk of type 2 diabetes 
and lipid disorders as well as cardiovascular diseases, 
cancer and musculoskeletal disorders. The risk of these 
disorders, however, has been found to be significantly 
lower among a small group of obese individuals, known 
as obese but metabolically healthy. Causes of health risks 
in metabolically “healthy” and “unhealthy” subjects 
are mainly observed in the accumulation of visceral fat 
which contributes to the development of hyperinsuli-
naemia and insulin resistance. Visceral fat accumulates 
primarily in the abdominal organs, mainly in the liver, 
pancreas and the mesentery as well as the heart, mus-
cles and blood vessels [1, 2]. Waist circumference and 
waist/hip ratio (WHR) measurements constitute simpler 
and indirect methods in assessing visceral fat build-
up. These methods also include bioelectric impedance 
and densitometry using dual beam radiation (DXA). 
Magnetic resonance imaging (MRI) and computed to-
mography (CT) of the abdomen provide more detailed 
measurements of visceral fat. Among these methods, 
DXA, which checks fat build-up in the abdomen but 
does not distinguish between subcutaneous and visceral 
fat, is considered the ‘gold standard’ as it is characterised 
by good specificity, reproducibility and a relatively low 
exposure to radiation [3]. The DXA tests conducted so 
far have, however, failed to determine the reference 
ranges for sex, age group or race.
Excess visceral fat is known to occur in obese indi-
viduals and in individuals with normal body mass index 
(BMI) alike. This observation originated the concept 
of MONW — metabolically obese but normal weight. 
MONW predisposes to hyperinsulinaemia/insulin re-
sistance and is often associated with elevated levels of 
triglyceride, hypertension, and nonalcoholic fatty liver 
disease [4, 5]. It is estimated that this type of obesity 
may occur in 10–18% of the population aged 20–40 [6] 
but the actual assessment of its occurrence is impeded 
by the lack of uniform MONW diagnostic criteria. In 
1988, Rudermann et al. introduced a diagnostic proce-
dure based on the evaluation of 22 attributes, each of 
which was assigned a specific number of points. The 
procedure, however, never gained universal acceptance. 
Subsequent research sought to simplify the complex cri-
teria in reference to the severity of insulin resistance by 
using the glucose clamping technique [7, 8] or by using 
indirect indicators calculated from the concentration of 
fasting insulin and glucose [3, 9], concentration of insu-
lin [10], the visceral fat mass in computed tomography 
of the abdomen [11, 16], the coexistence of impaired glu-
cose tolerance [17] or the metabolic syndrome [17–22]. 
Moreover, the correct body mass is defined in the cited 
literature as: BMI lower than 25 kg/m2 [6, 8, 11, 14, 15, 19, 
20], 26.3 kg/m2 or 27 kg/m2 [7, 10, 18]. Additionally, the 
prevalence of MONW occurrence may be influenced by 
age, sex and ethnic differences. This has been indicated 
by studies conducted on the Venezuelan population, 
among which 37% of individuals have been diagnosed 
with the MONW syndrome. In the United States, the 
occurrence of MONW has been more prevalent among 
Mexican and African Americans and Native Americans 
than among Caucasians [6].
The incidence of MONW in Poland is not known. 
That is why we have attempted to assess the scale of 
this phenomenon based on a study of a large, randomly 
chosen homogeneous population aged 20-40 in three 
large urban areas. An additional goal of the study was 
to identify the limit values of abdominal fat in men and 
women measured using the DXA method above which 
the risk of metabolic disorders increases.
Material and methods
Material
This study of a randomly selected group of people was 
conducted in three large urban areas of Poland (Szc-
zecin, Krakow and Wroclaw). The selection was based 
on local voter lists. Letters were sent to individuals aged 
from 20 to 40 inviting them to participate in the study. 
Subjects with no previously diagnosed carbohydrate 
metabolism disorders, chronic diseases requiring medi-
cal treatment or cancer were invited to participate in the 
research. Participation was voluntary and all individuals 
signed an informed consent form which was authorised 
by local bioethical committees in all three centres. 
The individuals who responded to the invitation 
were interviewed and underwent physical exami-
nation, on the basis of which men and women with 
normal BMI (less than 25 kg/m2) were selected for 
the study. The use of oral contraceptives or discon-
tinuation of their use within three months from the 
moment of volunteering to participate in the study 
was a disqualifying criterion for women. 855 people 
were accepted to take part in the research, comprising 
615 women and 240 men. 
Anthropometric measurements and body  
composition parameters
All subjects underwent the following anthropomet-
ric measurements: height, body mass, and waist and 
hip circumference. The waist/hip (WHR, waist-to-hip 
ratio) indicator was calculated based on the waist and 
hip measurements.
Body composition was estimated by the densitom-
etry method (DXA, dual X-ray absorptiometry) using 
measurements of the whole body. The tests were carried 
out in accordance with the standard protocol provided 
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by the manufacturer i.e. using the appropriate rules of 
automated positioning and irradiation conditions. The 
body composition parameters were measured with the 
following DXA equipment: 1) Lunar Prodigy Advance, 
GE Lunar Radiation Corporation, Madison, WI, USA (in 
Szczecin), 2) Lunar DPX-plus, Lunar Corporation, Madi-
son, WI, USA (in Wroclaw), and 3) Lunar DPX General 
Electric Healthcare, USA (in Krakow). In order to gauge 
the results, the DXA machines were cross-calibrated 
with the help of multiple measurements of whole-body 
phantoms in all three centres. The final results were pre-
sented in an adjusted form. The whole-body measure-
ments were used to calculate total body fat (BF) in grams 
and as a percentage of body fat (BF%). Fat distribution 
was analysed in the abdominal area (android) and the 
hip area (gynoid) (Fig. 1). Abdominal fat deposits (in 
grams and as a percentage of the android mass) were 
measured within the area between two horizontal lines 
running from the top edge of the L2 vertebra and the 
bottom edge of the L4 vertebra. Assessment of visceral 
fat within the said area is more conclusive as it contains 
a relatively small amount of subcutaneous fat [23]. The 
hip deposit (presented in grams and as a percentage of 
the gynoid mass) was measured in the area confined by 
a line connecting the greater trochanters of the femur 
from the top, and by a horizontal line running through 
the flexion gap in the knee joint from the bottom.
Biochemical evaluation
Each subject underwent determination of serum glu-
cose, insulin, total cholesterol, HDL cholesterol and 
triglycerides. Blood samples were collected in the morn-
ing, on an empty stomach and at least 12 hours after 
the last meal. The glucose concentration was tested by 
the enzymatic method on the Dimension Xpand ana-
lyser using tests developed by Dade Behring Marburg 
GmbH in Germany. The insulin concentration was 
measured by the immunoenzymatic method on the 
AxSYM analyser using systems by Abbott Diagnostics, 
USA. Fasting glucose and fasting insulin concentration 
levels were used to assess insulin sensitivity with the 
insulin resistance indicators: 
HOMA (homeostasis model assessment) = insulin [µIU/ 
/mL] ¥ glucose (mmol/L)/22.5 
FIRI (fasting insulin resistance index) = insulin [µIU/ 
/mL] ¥ glucose (mmol/L)/25
QUICKI (quantitative insulin sensitivity check index) 
= 1/[log (fasting insulin [µU/mL]) × log(fasting glucose 
[mg/dL])
Total cholesterol concentration and its HDL fraction 
as well as triglycerides were assessed through enzymatic 
methods using the systems by Dade Behring Marburg 
GmbH, Germany. LDL cholesterol concentration was 
calculated using the Friedewald formula [28].
MONW identification
Among the studied subjects, only 0.67% of women and 
0.9% of men with normal body weight met the meta-
bolic syndrome criteria as defined by the NCEP-ATP III 
and IDF standards; hence the definitions to diagnose 
MONW based on the coexistence of the syndrome with 
normal body weight [19] were not used. In subsequent 
analyses to diagnose MONW, the criteria specified by 
Conus et al. were employed; thanks to these criteria, 
MONW can be identified in individuals with HOMA 
> 1.69 [6].
Statistics
Elements of descriptive statistics were used in describing 
the variables such as: minimum and maximum values, the 
lower and upper quartile, the mean, the median, and the 
standard deviation; tables, histograms, as well as scatter 
diagrams, medians and confidence intervals for means.
The Shapiro-Wilk test was used to verify the compat-
ibility of the distribution of the studied characteristics 
with normal distribution. The distribution of most of the 
variables analyzed in this paper was significantly differ-
ent from the normal distribution, thus nonparametric 
methods were used to conduct the analysis.
The equality of distribution hypotheses were veri-
fied using the Kolmogorov-Smirnov test and the Mann-
Whitney test. Differences were considered statistically 
significant at p < 0.05, while at 0.05 < p < 0.1 differences 
were found to be on the border of statistical significance. 
The significance of the Spearman correlation be-
tween characteristics was analyzed using the Student’s 
t-test. The statistical significance was established at 
p < 0.05. The results found on the border of statistical 
significance (0.05 < p < 0.1) were also taken into con-
sideration. The cut-off point — the border value of the 
android deposit expressed in grams and percentage, 
was defined with the error rate of 20%.
Figure 1. Assessment of androidal and gynoidal fat (deposits)
Rycina 1. Miejsca pomiaru tłuszczu brzusznego i biodrowego
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The statistical calculations were done using Statistica 
9.0 software.
Results
Among 855 subjects, 202 (23.7%) were diagnosed with 
MONW, including 131 women (21.3%) and 71 men 
(29.6%). Individuals with HOMA < 1.69 belonged to 
a control group (C). Mean values of the anthropometric 
and body composition measurements as well as biochemi-
cal tests in the MONW subjects were compared to healthy 
individuals and are summarised in Table I (women) and 
Table II (men). With respect to the control group, both men 
and women with MONW had comparable body weight, 
waist and hip circumference as well as lean mass, while 
they showed significantly greater total fat content and its 
abdominal deposit. Additionally, greater concentration lev-
els of fasting glucose and fasting insulin were observed in 
MONW, along with worse insulin sensitivity and abnormal 
(atherogenic) profile of the blood lipids. The abdominal 
fat mass in all studied subjects positively correlated with 
the concentration levels of glucose, insulin, triglycerides, 
total cholesterol and its LDL-C as well as insulin sensitivity 
indicators. It negatively correlated with HDL-C and the 
QUICKI indicator. Also, a weak yet significant correlation 
between abdominal fat and blood pressure was observed 
(Table III). In terms of the hip fat deposit, no such corre-
spondence was discovered. 
Table I. Anthropometric features, fat distribution and biochemical parameters in MONW and C groups of women
Tabela I. Parametry antropometryczne, skład ciała i parametry biochemiczne w grupach kobiet MONW i C
C (n = 483) p MONW (n = 131)
Mean SD Mean SD
Age (years) 29.11 6.10 0.064 28.02 6.23
Weight [kg] 57.42 6.56 0.118 58.62 7.11
Height [cm] 164.97 5.74 0.427 165.39 5.85
BMI [kg/m2] 21.08 1.99 0.125 21.38 1.90
Waist circumference [cm] 71.06 6.12 0.123 71.78 6.23
Hip circumference [cm] 95.05 5.48 0.955 95.08 5.47
WHR 0.75 0.05 0.118 0.76 0.05
Systolic BP [mm Hg] 109.70 12.18 0.053 111.86 12.28
Diastolic BP [mm Hg] 70.98 8.95 0.604 71.14 8.64
Total fat [g] 16,252.4 4,240.7 0.026 17,300.9 4,662.6
Total fat (%) 29.38 5.68 0.006 30.91 5.98
Androidal deposit [g] 1,051.5 457.5 0.047 1,124.3 441.1
Androidal deposit (%) 22.83 6.85 0.031 24.23 6.88
Gynoidal deposit [g] 5,186.9 1,561.6 0.056 5,421.2 1,385.0
Gynoidal deposit (%) 35.28 5.50 0.029 36.34 5.53
Androidal deposit/gynoidal 
deposit
0.22 0.16 0.354 0.21 0.07
Glucose [mg/dL] 82.04 8.64  < 0.001 87.46 9.05
Insulin [µIU/mL] 5.02 1.76  < 0.001 10.86 3.09
HOMA 1.02 0.35  < 0.001 2.35 0.70
FIRI 0.91 0.32  < 0.001 10.86 3.09
QUICKI 0.39 0.03  < 0.001 0.34 0.01
Total cholesterol [mg/dL] 185.86 33.40 0.397 188.92 32.80
 HDL-C [mg/dL] 66.57 15.41  < 0.001 60.95 14.60
 LDL-C [mg/dL] 106.17 28.76 0.015 112.62 30.05
 LDL-C/HDL-C 1.69 0.64  < 0.001 1.97 0.76
 Triglycerides [mg/dL] 69.83 28.22  < 0.001 76.88 26.71
BMI — body mass index; WHR — waist-to-hip ratio
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Table II. Anthropometric features, fat distribution and biochemical parameters in MONW and C groups of men
Tabela II. Parametry antropometryczne, skład ciała i parametry biochemiczne w grupach mężczyzn MONW i C
C (n = 169) p MONW (n = 71)
Mean SD Mean SD
Age (years) 27.99 5.32 0.854 28.25 5.66
Weight [kg] 72.19 8.10 0.460 72.84 7.44
Height [cm] 180.29 6.77 0.193 178.85 6.31
BMI[kg/m2] 22.18 1.87 0.043 22.74 1.62
Waist circumference [cm] 82.09 6.78 0.132 83.48 6.01
Hip circumference [cm] 97.36 4.89 0.350 97.84 5.17
WHR 0.84 0.05 0.101 0.85 0.05
Systolic BP [mm Hg] 117.30 12.29 0.536 115.89 11.32
Diastolic BP [mm Hg] 75.63 9.96 0.710 76.10 10.30
Total fat [g] 11,941.8 4,696.0 0.014 SD 4,631.0
Total fat (%) 17.09 5.89 0.006 19.22 5.67
Androidal deposit [g] 1,041.7 528.01 0.084 1,159.0 536.5
Androidal deposit (%) 17.51 6.80 0.047 19.37 6.62
Gynoidal deposit [g] 3,157.5 1,225.8 0.065 3,499.4 1,334.6
Gynoidal deposit (%) 18.43 5.91 0.020 20.43 6.27
Androidal deposit/gynoidal deposit 0.33 0.10 0.835 0.34 0.13
Glucose [mg/dL] 86.17 8.96 0.011 90.0 9.85
Insulin [µIU/mL] 4.90 1.84  < 0.001 10.46 2.92
HOMA 1.04 0.39  < 0.001 2.32 0.72
FIRI 0.999 0.315  < 0.001 2.207 0.534
QUICKI 0.383 0.031  < 0.001 0.335 0.01
Total cholesterol [mg/dL] 183.71 34.80 0.119 192.18 37.12
 HDL-C [mg/dL] 57.28 13.20 0.255 55.18 13.62
LDL-C [mg/dL] 109.82 33.23 0.102 117.86 33.85
LDL-C/HDL-C 2.04 0.86 0.058 2.28 0.90
Triglycerides [mg/dL] 82.13 34.41 0.224 95.80 52.23
Table III. Correlations between abdominal fat and anthropometric features with biochemical parameters
Tabela III. Korelacje pomiędzy masą tłuszczu brzusznego a parametrami antropometrycznymi i biochemicznymi
Androidal deposit [g] Abdominal fat Anthropometric features
R p R p
Glucose [mg/dL] 0.130 0.001 0.132 0.049
Insulin [µIU/mL] 0.168  < 0.0001 0.162 0.015
HOMA 0.189  < 0.0001 0.167 0.013
QUICKI –0.189  < 0.0001 –0.167 0.013
FIRI 0.189  < 0.0001 0.167 0.013
Total cholesterol [mg/dL] 0.085 0.038 0.318  < 0.0001
LDL-C [mg/dL] 0.153 0.0001 0.346  < 0.0001
HDL-C [mg/dL] –0.195  < 0.0001 –0.179 0.007
LDL-C/HDL-C 0.227  < 0.0001 0.363  < 0.0001
Triglycerides [mg/dL] 0.162  < 0.0001 0.182  < 0.0001
Systolic BP [mm Hg] 0.114 0.004 0.201 0.002
Diastolic BP [mm Hg] 0.154  < 0.001 0.202 0.002
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The limit value for abdominal fat was calculated 
in the subsequent phase. Beyond the threshold of the 
limit value, the prevalence of at least two out of five 
risk factors of type 2 diabetes increases along with car-
diovascular diseases [15]: 1) HOMA > 1.69, 2) glucose 
> 100 mg/dL, 3) triglycerides 150 mg/dL, 4) HDL-C < 50 
mg/dL for women and < 40 mg/dL for men, and blood 
pressure 130/85 mm Hg. The frequency of manifestation 
of the factors increases significantly when the mass of 
abdominal fat in women is greater than 1,496.8 grams 
which amounts to 30.2 % (OR = 2.0726, –95% CI — 
1.0495, +95% CI — 4.0933), and 2,013.2 grams and 28.3% 
in men respectively (OR = 0.4625, –95% CI — 0.0579, 
+ 95% CI — 3.6912). Women with the android mass 
above the cut-off point (excess abdominal fat or EAF) 
had significantly greater BMI, body mass and waist and 
hip circumference, as well as increased WHR blood pres-
sure than women with abdominal fat values below the 
cut-off point (normal abdominal fat or NAF) (Table IV).
Furthermore, in comparison with NAF, the EAF 
group was found to manifest higher fasting insulin 
and glucose levels, significantly worse insulin sensitiv-
ity and an adverse lipid profile (an increased TG and 
LDL-C concentration and decreased HDL-C). Similar 
differences in BMI and waist and hip circumference 
were observed between NAF and EAF men (Table V). 
However, in contrast with women, no significant dif-
ferences were found between the two groups of men 
in terms of blood pressure, glucose and insulin concen-
tration or insulin sensitivity indicators. Men with EAF 
had a higher concentration of LDL-C and lower HDL-C 
than men with NAF. 
Discussion
The concept of MONW evolved in the 1980s. It was 
then that Ruderman et al. indicated the existence of 
non-obese individuals who, despite normal body 
weight, developed complications of obesity as well 
as type 2 diabetes, hypertension, dyslipidaemia and 
coronary heart disease. They also discovered that hy-
perinsulinaemia was the key to these disorders [4, 5]. 
In the etiology of MONW, special attention was paid 
to the excess accumulation of abdominal fat and low 
physical activity. It is crucial to identify such individu-
als, as early treatment of metabolic disorders through 
lifestyle modifications and possible pharmacotherapy 
can prove helpful in avoiding serious complications 
Table IV. Anthropometric features, fat distribution and biochemical parameters in NAF and EAF groups of women
Tabela IV. Parametry antropometryczne, skład ciała i parametry biochemiczne w grupach kobiet NAF i EAF
NAF (n = 520) p EAF (n = 94)
Mean SD Mean SD
Age (years) 28.56 6.12 0.01 30.35 6.10
Weight [kg] 56.69 6.34  < 0.0001 62.89 5.29
Height [cm] 165.19 5.73 0.103 164.24 5.69
BMI [kg/m2] 20.74 1.81  < 0.0001 23.29 1.21
Waist circumference [cm] 69.88 5.28  < 0.0001 78.26 5.50
Hip circumference [cm] 94.41 5.26  < 0.0001 98.74 4.35
WHR 0.74 0.04  < 0.0001 0.79 0.05
Systolic BP [mm Hg] 109.11 11.79 0.001 113.63 13.26
Diastolic BP [mm Hg] 70.16 8.49  < 0.0001 74.94 9.87
Glucose [mg/dL] 82.76 9.15 0.014 85.35 8.05
Insulin [µIU/mL] 6.16 3.16 0.012 6.99 3.32
HOMA 1.26 0.69 0.002 1.48 0.75
QUICKI 0.37 0.03 0.002 0.36 0.03
FIRI 1.14 0.62 0.002 1.33 0.67
Total cholesterol [mg/dL] 186.09 32.84 0.232 189.66 35.18
HDL-C[mg/dL] 66.31 15.69 0.0002 60.24 12.63
LDL-C [mg/dL] 106.41 28.81 0.015 114.80 29.37
LDL-C/HDL-C 1.70 0.64 0.0001 2.0 0.74
Triglycerides [mg/dL] 69.55 26.53 0.001 80.54 32.31
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connected with lowered death risk such as type 2 
diabetes or ischaemic heart disease. The frequency of 
MONW occurrence is difficult to establish due to the 
lack of uniform diagnostic criteria; studies carried out 
thus far have been conducted among various age and 
ethnic groups. No optimal parameters for diagnosing 
MONW have been created which renders it challeng-
ing to study the incidence of the syndrome in different 
populations or countries.
There are no case studies of MONW in women and 
men between 20 and 40 years of age in the Polish lit-
erature. A study of postmenopausal women conducted 
in Wroclaw revealed that the phenotype of metabolic 
obesity with normal body weight constitutes about 
10.1% [24]. 
The epidemiological data collected thus far has 
proved divergent, equivocal and challenging to com-
pare due to the lack of uniform standards for identify-
ing MONW individuals. The commonest criterion in 
Polish literature is the limit values of insulin resistance 
parameters. The consequences of insulin resistance are 
metabolic disorders which occur in obese and non-obese 
individuals alike. In the study of the Polish population, 
a criterion similar to that of Conus et al. was used. Ac-
cording to the criterion, the value of HOMA ≥ 1.69 clas-
sifies a normal-weight individual in the MONW group. 
Using the above criterion, 202 individuals (23.65%) 
were placed in the MONW group and 652 subjects in 
the control group (C group); after taking gender into 
account, 131 patients (21.34%) classified in the MONW 
among women. Among men, 71 individuals (29.58%) 
were placed in the MONW group. Conus et al. dem-
onstrated the presence of MONW in approx. 10% of 
women. The larger percentage of women with insulin 
resistance among residents of Szczecin, Krakow and 
Wroclaw may stem from the age difference among the 
studied groups – Polish men and women were older 
[6]. The study conducted by Jennings et al. showed 
that the prevalence of MONW in women is similar to 
that in the Polish population and amounts to 22%. The 
researchers employed a similar identification criterion, 
i.e. HOMA ≥ 1.95 [9]. Italian researchers obtained similar 
results and concluded that 20% of non-obese women 
and men manifested impaired insulin secretion and 
action. In a group of Venezuelan patients, MONW 
was diagnosed more often, up to 56% of boys and 43% 
of girls between the ages of 14 and 17 [10]. This high 
prevalence of MONW diagnosis stems from rigorous 
Table V. Anthropometric features, fat distribution and biochemical parameters in NAF and EAF groups of men NAF
Tabela V. Parametry antropometryczne, skład ciała i parametry biochemiczne w grupach mężczyzn NAF i EAF
 NAF (n = 222) p EAF (n = 18)
Mean SD Mean SD
Age (years) 27.74 5.33 p > 0.10 30.61 6.00
Weight [kg] 72.06 7.84 p < 0.025 77.88 5.32
Height [cm] 179.81 6.71 p > 0.10 179.50 5.62
BMI [kg/m2] 22.25 1.71 p < 0.001 24.15 0.74
Waist circumference [cm] 82.18 6.30 p < 0.001 89.69 4.20
Hip circumference [cm] 97.14 4.85 p < 0.025 101.88 4.35
WHR 0.84 0.04 p < 0.005 0.88 0.04
Systolic BP [mm Hg] 116.83 12.10 p < 0.10 122.72 8.60
Diastolic BP [mm Hg] 75.65 9.92 p < 0.10 80.50 6.35
Glucose [mg/dL] 87.72 9.34 p > 0.10 87.74 8.23
Insulin [µIU/mL] 6.48 3.35 p < 0.10 7.66 3.62
HOMA 1.42 0.78 p > 0.10 1.65 0.76
FIRI 1.44 0.71 p > 0.10 1.13 0.73
QUICKI 0.40 0.47 p > 0.10 0.52 0.17
[mg/dL] 184.17 35.52 p < 0.01 210.72 30.81
HDL-C [mg/dL] 56.61 13.53 p > 0.10 52.66 11.87
LDL-C [mg/dL] 109.98 32.80 p < 0.005 141.27 31.38
 LDL-C/HDL-C 2.07 0.85 p < 0.005 2.81 0.87
Triglycerides [mg/dL] 83.66 42.46 p > 0.10 87.15 29.31
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diagnostic criteria used by the researchers. Ferrannini 
et al. discovered insulin resistance in 10% of studied 
European men and women with BMI below 25 kg/m2 [25]. 
Dvorak et al. found the presence of MONW in 18% of 
Caucasian, Asian and Hispanic subjects [7]. Similarly, 
Goodpaster et al. identified metabolic obesity with 
normal weight in 14% of American men and 22% of 
American women [17].
In light of the lack of strictly defined diagnostic 
criteria for MONW, researchers in Japan, Korea and 
the United States employed the metabolic syndrome 
criteria according to the NCEP ATP III guidelines. 
When the metabolic syndrome criterion was taken 
into account, MONW was diagnosed in 12.7% of 
women and men in the Lee et al. study and in 15.2% 
of subjects in the Tsai et al. study [21, 22]. In another 
cross-sectional analysis of 3,747 non-obese women 
(BMI 18.5–27.0 kg.m2) the metabolic syndrome was 
found in 11% of African and Hispanic Americans 
as well as in 6% of Caucasian women [18]. Meigs 
et al. identified the metabolic syndrome in 7.1% of 
individuals with normal body weight, while insulin 
resistance was diagnosed in 7.7% of subjects [19]. 
Among the population of Polish young men and 
women with normal body weight, prevalence of the 
metabolic syndrome, in compliance with criteria es-
tablished by five international science organisations 
in 2009 (IDF, AHA, IAS, WHF, and NHLBI), was found 
in only 0.67% of women and 0.9% of men. 
It is known that excessive abdominal fat causes 
insulin resistance. Some researchers classify non-obese 
individuals as MONW or NOW based on the high con-
tent of abdominal fat evaluated on TC scans [11]. Hyun 
et al. as well as Katsuki et al. concluded that 18.5% of 
women and men with a surface area of fat greater than 
100 cm2 face a greater probability of developing cardio-
vascular diseases [12, 13, 15]. Criteria for the diagnosis 
of excess accumulation of fat in the visceral area are not 
unequivocal. A number of researchers believe that the 
adipose tissue content on CT scans at the L4–L5 level 
greater than 110 cm2 is associated with the occurrence of 
ischaemic heart disease [26]. Despress and Lamarche as-
sumed a value of 100 cm2 as the limit amount of visceral 
tissue [27]. Others have demonstrated that an area of 
visceral fat above 130 cm2 contributes to dyslipidaemia 
and insulin resistance [28]. Due to the lack of uniform 
criteria in assessing the accumulation of excess abdomi-
nal fat, a limit value of the android deposit at which 
metabolic disorders occur has been introduced in this 
paper. Women with abdominal fat above 30.21% and 
men with abdominal fat above 28.31% were classified as 
MONW. Considering the above criterion of the android 
deposit limit value, 15.31% of women and 7.50% of men 
with normal BMI  < 25 kg/m2 had excess abdominal fat. 
The study results of the Polish population are congruent 
with the studies carried out by Hyun et al. and Katsuki 
et al. [11, 12, 15].
In the absence of consistent diagnostic criteria, it is 
not possible to make an accurate assessment of the dis-
cussed pathology, nor is it feasible to draw comparisons 
between given populations. The divergence in MONW 
prevalence is connected with the variety of methods 
used to identify MONW individuals. 
It can be concluded that approximately 21.34% of 
women and 29.58% of men with normal body weight 
among the residents of Szczecin, Krakow and Wroclaw 
manifest impaired insulin sensitivity; 15.31% of non-
obese women and 7.5% of non-obese men show the 
accumulation of excess abdominal fat.
Conclusions
As no uniform criteria for diagnosing MONW are 
available, it is not possible to make an accurate assess-
ment of the disorder or draw comparisons between 
given populations. The divergence in MONW preva-
lence is connected with the variety of methods used 
to identify MONW individuals. It can be concluded 
that approximately 21.34% of women and 29.58% of 
men with normal body weight among the residents 
of Szczecin, Krakow and Wroclaw manifest impaired 
insulin sensitivity; 15.31% of non-obese women and 
7.5% of non-obese men show the accumulation of 
excess abdominal fat. The increased amount of ab-
dominal fat in people with normal body weight is 
connected with the presence of insulin resistance and 
adverse atherogenic lipid profile. Existing metabolic 
disorders in seemingly non-obese individuals may 
lead to future cardiovascular diseases.
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